Management highlighted accelerating momentum in the data center market with an approximately $400 million backlog and is expanding capacity—including domestic large‑megawatt manufacturing expected to ...

Generac Holdings Inc. (GNRC) reported fourth quarter results that missed Wall Street estimates for revenue and adjusted earnings, but strong momentum in data center demand and a bullish 2026 outlook ...

Generac (GNRC) surged 57% year-to-date despite missing Q4 earnings expectations. The rally reflects a pivot to data center power infrastructure. Generac positioned itself as key supplier to hyperscale ...

Generac Holdings Inc. GNRC has reported fourth-quarter 2025 adjusted earnings per share (EPS) of $1.61, which missed the Zacks Consensus Estimate of $1.81. GNRC had registered an adjusted EPS of $2.80 ...

Generac reported a 2% sales decrease to $4.21 billion for the 2025 fiscal year. The company's annual profit fell to $159.5 million, down from $316 million the previous year. A key factor in the sales ...

Generac is reiterated as a "Buy," with a raised price target of $231, driven by strong momentum and AI-driven data center demand. Despite Q4 misses—EPS of $1.61 and an 11% revenue decline—GNRC surged ...

Aaron Jagdfeld, Generac CEO, joins 'The Exchange' to discuss the company's quarterly earnings results, its data center operations and much more. Got a confidential news tip? We want to hear from you.

Ancestor modules are the latest chase items in The First Descendant. They are character-specific mods that allow you to have custom stats on them, making your characters even stronger. Using them can ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

Observation is the current standard of care for smoldering multiple myeloma. We hypothesized that early intervention with lenalidomide could delay progression to symptomatic multiple myeloma. One ...